JPS61195359A - 澄明な血清の製造法 - Google Patents
澄明な血清の製造法Info
- Publication number
- JPS61195359A JPS61195359A JP60036223A JP3622385A JPS61195359A JP S61195359 A JPS61195359 A JP S61195359A JP 60036223 A JP60036223 A JP 60036223A JP 3622385 A JP3622385 A JP 3622385A JP S61195359 A JPS61195359 A JP S61195359A
- Authority
- JP
- Japan
- Prior art keywords
- serum
- obtd
- supernatant
- ultrafiltration
- soln
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002966 serum Anatomy 0.000 title claims abstract description 45
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims abstract description 16
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 239000006228 supernatant Substances 0.000 claims abstract description 11
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 8
- 229910001629 magnesium chloride Inorganic materials 0.000 claims abstract description 8
- 239000011734 sodium Substances 0.000 claims abstract description 8
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 8
- 239000002244 precipitate Substances 0.000 claims abstract description 7
- 108010007622 LDL Lipoproteins Proteins 0.000 claims description 5
- 102000007330 LDL Lipoproteins Human genes 0.000 claims description 5
- 108010062497 VLDL Lipoproteins Proteins 0.000 claims description 5
- 238000000108 ultra-filtration Methods 0.000 abstract description 7
- 238000003860 storage Methods 0.000 abstract description 5
- 238000004108 freeze drying Methods 0.000 abstract description 2
- 239000012528 membrane Substances 0.000 abstract description 2
- 239000002808 molecular sieve Substances 0.000 abstract description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 abstract description 2
- 102000004895 Lipoproteins Human genes 0.000 abstract 2
- 108090001030 Lipoproteins Proteins 0.000 abstract 2
- 230000005484 gravity Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 238000004321 preservation Methods 0.000 abstract 1
- 230000000284 resting effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 238000005238 degreasing Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 101710201961 Virion infectivity factor Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000004848 nephelometry Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60036223A JPS61195359A (ja) | 1985-02-25 | 1985-02-25 | 澄明な血清の製造法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60036223A JPS61195359A (ja) | 1985-02-25 | 1985-02-25 | 澄明な血清の製造法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS61195359A true JPS61195359A (ja) | 1986-08-29 |
| JPH0513271B2 JPH0513271B2 (https=) | 1993-02-22 |
Family
ID=12463775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60036223A Granted JPS61195359A (ja) | 1985-02-25 | 1985-02-25 | 澄明な血清の製造法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS61195359A (https=) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5517492A (en) * | 1978-07-17 | 1980-02-06 | Beckman Instruments Inc | Production of biological composition used as serum standard composition for diagnostic analysis |
| JPS5578255A (en) * | 1978-12-08 | 1980-06-12 | Kyorin Pharmaceut Co Ltd | Simultaneous simple and quick measurement method for low and high specific gravity lipo protein cholesterol and its measuring kit |
-
1985
- 1985-02-25 JP JP60036223A patent/JPS61195359A/ja active Granted
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5517492A (en) * | 1978-07-17 | 1980-02-06 | Beckman Instruments Inc | Production of biological composition used as serum standard composition for diagnostic analysis |
| JPS5578255A (en) * | 1978-12-08 | 1980-06-12 | Kyorin Pharmaceut Co Ltd | Simultaneous simple and quick measurement method for low and high specific gravity lipo protein cholesterol and its measuring kit |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0513271B2 (https=) | 1993-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kekwick et al. | The purification of human fibrinogen | |
| Edsall | The plasma proteins and their fractionation | |
| US4045176A (en) | Preparation of optically clear serum | |
| Cohn | The properties and functions of the plasma proteins, with a consideration of the methods for their separation and purification. | |
| Jorpes | The protein component of the erythrocyte membrane or stroma | |
| Markus et al. | The disulfide bonds of human serum albumin and bovine γ-globulin1 | |
| Seibert et al. | Molecular weight, electrochemical and biological properties of tuberculin protein and polysaccharide molecules | |
| Robertson | The physical chemistry of the proteins | |
| Cohn | Chemical, physiological, and immunological properties and clinical uses of blood derivatives | |
| JPS61142467A (ja) | 脂質診断学用の管理血清もしくは検定用血清及びその製造法 | |
| CA2183654A1 (en) | Protein calibrator/control product | |
| Burnstine et al. | Solubility of bilirubin in aqueous solutions. | |
| Kawahara | Evaluation of diffusion coefficients of proteins from sedimentation boundary curves | |
| Grütter et al. | Studies on the molecular weight of the adenovirus type 2 hexon and its subunit | |
| Wilf et al. | Acceleration of fibrin gel formation by unrelated proteins | |
| Ogston et al. | Studies on the heterogeneity of crystallized β-lactoglobulin | |
| Halliday et al. | Electrophoretic analysis of the sera of young rats | |
| Jernej et al. | A simple and reliable method for monitoring platelet serotonin levels in rats | |
| Booth | Carbonic anhydrase activity inside corpuscles. Enzyme-substrate accessibility factors | |
| Cox et al. | The molecular weights of porcine plasma high density lipoprotein and its subunits | |
| JPS61195359A (ja) | 澄明な血清の製造法 | |
| Landis et al. | Interactions of bovine fibrinogen and thrombin: Early events in the development of clot structure | |
| Scudder | STUDIES IN BLOOD PRESERVATION*: THE STABILITY OF PLASMA PROTEINS | |
| Chantarangkul et al. | An Artificial ‘Haemophilic’Plasma for One‐Stage Factor‐VIII Assay | |
| Toon et al. | Permeability and reflection coefficients of urea and small amides in the human red cell |